1. Home
  2. EDRY vs PMN Comparison

EDRY vs PMN Comparison

Compare EDRY & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EuroDry Ltd.

EDRY

EuroDry Ltd.

N/A

Current Price

$60.79

Market Cap

72.8M

ML Signal

N/A

Logo ProMIS Neurosciences Inc. (ON)

PMN

ProMIS Neurosciences Inc. (ON)

N/A

Current Price

$9.24

Market Cap

84.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EDRY
PMN
Founded
2018
2004
Country
Greece
Canada
Employees
N/A
N/A
Industry
Marine Transportation
Pharmaceuticals and Biotechnology
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.8M
84.1M
IPO Year
2018
2022

Fundamental Metrics

Financial Performance
Metric
EDRY
PMN
Price
$60.79
$9.24
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
8
Target Price
★ $45.33
$42.71
AVG Volume (30 Days)
★ 182.9K
31.5K
Earning Date
11-12-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$40.95
N/A
Revenue Next Year
$8.53
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.95
$0.29
52 Week High
$73.07
$27.40

Technical Indicators

Market Signals
Indicator
EDRY
PMN
Relative Strength Index (RSI) 55.24 29.40
Support Level $17.86 $9.20
Resistance Level $73.07 $15.37
Average True Range (ATR) 6.40 0.92
MACD -0.46 -0.25
Stochastic Oscillator 50.24 9.92

Price Performance

Historical Comparison
EDRY
PMN

About EDRY EuroDry Ltd.

EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.

Share on Social Networks: